Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 15/20 | 0.42 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309743 | 0.85 | MTNR1A (0.34) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL4385656 | 0.85 | CA2 (0.35) | HSD17B10 | |
| SCHEMBL1309245 | 0.82 | MTNR1A (0.39) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1310162 | 0.82 | MTNR1A (0.39) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1309281 | 0.80 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL5428544 | 0.80 | MTNR1A (0.38) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1310030 | 0.74 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1308837 | 0.68 | MTNR1A (0.57) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL9988696 | 0.66 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL1308979 | 0.65 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | ADRB2, ADRB1, ADRA2B | MTNR1A 261/4885MTNR1B 180/4885NQO2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.